The global assisted reproductive technology market size was valued at USD 31.63 billion in 2025 and is projected to grow from USD 35.09 billion in 2026 to USD 80.58 billion by 2034, registering a CAGR of 10.95% during the forecast period from 2026 to 2034. Europe dominated the assisted reproductive technology market with a market share of 38.6% in 2025.
Assisted reproductive technology (ART) refers to a group of medical procedures used to help individuals and couples achieve pregnancy by handling eggs, sperm, or embryos under controlled laboratory conditions. These procedures include in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), embryo freezing, and embryo transfer. ART is widely used to address infertility, genetic conditions, and age-related reproductive challenges while improving the chances of successful conception.
Download a Free Sample To learn more about this report,
Integration of Artificial Intelligence in Embryo Selection and IVF Workflows
The Assisted Reproductive Technology Market analysis shows that embryo selection depends heavily on morphological assessment, which encourages fertility laboratories to use AI and deep-learning algorithms to analyze embryo images and developmental patterns. This transition is making embryo assessment more standardized and data-driven, resulting in faster and more objective embryo prioritization while clinical validation remains an important requirement. For example, a multicenter randomized trial involving 1,066 IVF patients found a clinical pregnancy rate of 46.5% with AI-based embryo selection compared with 48.2% with conventional morphology-based selection, showing that AI has reached clinical evaluation but does not yet demonstrate superiority over standard assessment.
Development of Non-Invasive Embryo Assessment Technologies
The need to evaluate embryo quality without removing cells from the embryo is encouraging researchers to examine spent culture media, cell-free DNA, metabolites, and time-lapse imaging as non-invasive assessment methods. This transition is reducing reliance on embryo biopsy for emerging testing approaches and could provide additional information about embryo developmental and genetic potential while preserving embryo integrity. For example, studies have detected embryonic cell-free DNA in spent culture media, although systematic reviews note that its accuracy and clinical reliability still require further validation before routine use.
Delayed Parenthood and Fertility Preservation Drive Market
Later family formation reduces the reproductive window and can increase the need for fertility evaluation and assisted reproductive services. Female fecundity declines with age as both the number and quality of oocytes decrease, creating greater treatment requirements among people postponing parenthood. For example, the WHO Bulletin reports that the proportion of women able to conceive and give birth within a year falls from about 75% at age 30 to 66% at 35 and 44% at 40. This age-related fertility pattern supports the use of IVF and other assisted reproductive procedures among individuals seeking pregnancy at later reproductive ages.
The availability of fertility preservation services creates an additional pathway for individuals seeking to protect their future reproductive options. ASRM recognizes mature oocyte cryopreservation as an established fertility-preservation technique and notes that planned oocyte cryopreservation can help individuals extend their reproductive window. For example, individuals may cryopreserve mature oocytes before treatments that could impair fertility or before postponing family formation. This service availability supports demand for ovarian stimulation, oocyte retrieval, cryopreservation, storage, and subsequent assisted reproductive procedures.
Treatment Costs and Variable Success Rates Restrain Market Expansion
High treatment and medication costs make assisted reproductive technology less affordable, particularly for patients who require multiple treatment cycles or additional procedures.Limited insurance coverage and high out-of-pocket expenses can discourage patients from starting or continuing treatment. These affordability barriers can reduce patient access and slow the growth of the assisted reproductive technology market.
Variable treatment success rates depend on factors such as patient age, infertility causes, egg and sperm quality, and treatment methods. Uncertainty around treatment outcomes can make patients hesitant to undergo costly procedures, especially when multiple cycles may be needed. This uncertainty can reduce treatment adoption and limit demand for assisted reproductive technology services.
At-Home Testing and Remote Fertility Care Offers Growth Opportunities
Diagnostic companies, fertility clinics, and digital health providers can offer home-based tests for ovulation, hormone levels, and male fertility indicators. Proov offers at-home fertility tests, including an FDA-cleared PdG test and a male fertility test priced at $99, creating revenue through direct-to-consumer testing and follow-up services. Such solutions can support market growth by extending fertility testing beyond clinics.
Fertility clinics and digital health providers can use virtual consultations, treatment tracking, and digital patient platforms to reach patients outside traditional clinics. Maven Clinic currently supports more than 15 million lives and works with over 2,300 employers and health plans, while Kindbody provides virtual fertility consultations and personalized fertility plans. These services create revenue through virtual consultations, employer contracts, and digital care programs, supporting market growth.
Specialized Workforce and Legal Complexity Hinders Growth
ART procedures require reproductive endocrinologists, embryologists, nurses, and other trained laboratory personnel with specialized expertise. The U.S. Bureau of Labor Statistics projects 9% employment growth for medical scientists from 2024 to 2034, reflecting continued demand for specialized scientific expertise in healthcare and research. Limited availability of appropriately trained ART professionals can restrict clinic capacity, increase waiting times, and make geographic expansion more difficult.
ART providers must navigate varying requirements covering embryo storage, donor gametes, genetic testing, surrogacy, and embryo disposition across jurisdictions. The U.S. CDC notes that ART is subject to federal reporting requirements, while individual states may impose additional laws and regulations governing fertility services. Such regulatory variation can increase compliance complexity and make it more difficult for providers to standardize services and expand across markets.
The in vitro fertilization (ivf) segment accounted for a 83.2% share in 2025 and is expected to grow at a CAGR of 8.96% during the forecast period 2026-2034, driven by its widespread use in the treatment of infertility, high success rates across various patient groups, and continued advancements in assisted reproductive technologies. the increasing prevalence of infertility and growing adoption of advanced ivf procedures further strengthen the segment’s dominant position in the assisted reproductive technology market.
The artificial insemination (ai) segment supports fertility treatment through less invasive procedures that facilitate sperm placement within the reproductive tract. the segment benefits from its comparatively lower procedural complexity, accessibility, and use among patients requiring alternative fertility treatment options.
Request Customizationto receive a tailored report.
The frozen non-donor segment accounted for a 38.1% share in 2025 and is expected to grow at a CAGR of 9.42% during the forecast period 2026-2034, driven by increasing demand for fertility preservation, greater flexibility in treatment scheduling, and growing adoption of frozen embryo transfer procedures. the rising use of cryopreservation technologies and improvements in embryo storage further strengthen the segment’s dominant position in the assisted reproductive technology market.
The fresh non-donor segment supports IVF procedures using freshly retrieved eggs and sperm from the intended parents, while the fresh donor segment caters to patients requiring donor eggs or sperm for fertility treatment. the frozen donor segment contributes through the use of cryopreserved donor eggs or embryos, offering greater treatment flexibility and improved availability of donor material.
The intrauterine (IUI) segment accounted for a 61.5% share in 2025 and is expected to grow at a CAGR of 7.91% during the forecast period 2026-2034, driven by its widespread use as a relatively simple and minimally invasive fertility treatment, along with increasing adoption among patients requiring assisted conception. the growing prevalence of infertility and expanding access to fertility clinics further strengthen the segment’s dominant position in the assisted reproductive technology market.
The intravaginal (IVI) segment supports fertility treatment through the placement of sperm within the vaginal canal, while the intracervical (ICI) segment involves placing sperm near the cervix to facilitate conception. the intratubal (ITI) segment supports assisted conception by delivering sperm directly into the fallopian tubes and is used in selected fertility treatment applications.
The instruments and equipment segment accounted for a share of 42.8% in 2025, owing to the widespread use of specialized instruments and equipment across IVF, artificial insemination, embryo handling, and other assisted reproductive procedures. the increasing number of fertility treatments and continued adoption of advanced reproductive technologies further strengthen the segment’s dominant position in the assisted reproductive technology market.
The software and AI solutions segment is expected to grow at a CAGR of 11.42% during the forecast period, driven by increasing adoption of artificial intelligence, data analytics, and digital technologies for embryo assessment, treatment planning, and fertility clinic management. the accessories and disposables segment supports assisted reproductive procedures through essential consumables and specialized products, while the culture media segment contributes by providing controlled environments for embryo development and cell culture during fertility treatments.
The fertility clinics and specialized facilities segment accounted for a 78.4% share in 2025 and is expected to grow at a CAGR of 9.03% during the forecast period 2026-2034, driven by the increasing number of fertility treatment procedures, growing availability of specialized reproductive healthcare services, and rising patient preference for dedicated fertility centers. the expansion of assisted reproductive technology services and increasing investments in specialized fertility infrastructure further strengthen the segment’s dominant position in the assisted reproductive technology market.
The hospitals and other medical settings segment supports assisted reproductive procedures through access to specialized medical professionals, advanced healthcare infrastructure, and integrated diagnostic and treatment services. the segment benefits from the availability of comprehensive medical care and the growing adoption of fertility treatments within hospital-based healthcare settings.
Speak to an Analystto discuss market opportunities.
The Europe assisted reproductive technology market accounted for the largest regional share of 38.6% in 2025, driven by established fertility care infrastructure, increasing demand for assisted reproductive procedures, and growing adoption of advanced fertility technologies. In the U.K. assisted reproductive technology market, IVF remains a significant component of fertility treatment, with national activity supported through NHS-funded and privately funded services. UK Parliament has highlighted substantial regional variation in access to NHS-funded IVF across England, reflecting differences in local funding policies and eligibility criteria. This variation in treatment access remains an important factor shaping the U.K. assisted reproductive technology market.
In the Germany assisted reproductive technology market, the German IVF Register documented 134,281 assisted reproductive treatment cycles in 2024 across 139 reporting centers, involving 69,890 women. Cryopreservation-related cycles continued to increase, while pregnancy rates per embryo transfer reached 30.5% for fresh cycles and 31.5% for frozen cycles, reflecting ongoing utilization of advanced reproductive technologies. Meanwhile, the France assisted reproductive technology market recorded high activity in 2025, with more than 12,000 requests for sperm-donation-assisted reproduction from female couples and single women. The number of egg donors also exceeded 1,000 for the first time, reaching 1,050 in 2025, while more than 2,700 people remained on the waiting list for egg-donation treatment at the end of the year.
Unlock Regional Insightsto access country-level data, & regional trends.
The Asia Pacific assisted reproductive technology market is expected to grow at a CAGR of 10.46%, showcasing the fastest-growing regional market, supported by rising infertility rates, expanding fertility care infrastructure, and increasing awareness and adoption of assisted reproductive procedures. In Japan, the Ministry of Health, Labour and Welfare continues to support assisted reproductive medicine through insurance coverage for in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and related reproductive treatments. The ministry also maintains programs supporting fertility preservation and assisted reproductive treatment after fertility-preservation procedures, with the relevant program guidelines partially revised in April 2026.
In China, the National Health Commission reported in June 2026 that the number of approved assisted reproductive institutions had reached 645 nationwide, while the country continues to advance regulated application of assisted reproductive technology under its 2026–2030 health and childbirth-support policies, including efforts to standardize infertility diagnosis and treatment and increase coverage for appropriate assisted reproductive technologies. In South Korea, the Ministry of Health and Welfare provides nationwide infertility treatment support, including assisted reproductive procedures, with current support covering up to 20 IVF procedures and 5 artificial insemination procedures per childbirth, alongside pre-pregnancy health-management services for men and women aged 20–49. In India, the Central Drugs Standard Control Organization issued a June 2026 notice covering the sale of IVF media, reagents, and related consumables used in assisted reproductive technology procedures, while a March 2026 circular addressed medical devices intended for IVF and IUI procedures, including IUI kits and sperm-washing centrifuges, supporting the development of the assisted reproductive technology ecosystem.
The North America assisted reproductive technology market accounted for a regional share of 29.4% in 2025, supported by advanced healthcare infrastructure, high adoption of fertility treatments, and increasing demand for specialized reproductive healthcare services. The U.S. assisted reproductive technology market is supported by substantial clinical utilization, with the U.S. Centers for Disease Control and Prevention reporting 435,426 assisted reproductive technology cycles in 2022 across 457 reporting clinics, resulting in 94,039 live-birth deliveries and 98,289 live-born infants. Infants conceived through assisted reproductive technology accounted for about 2.6% of all infants born in the U.S.
The Canada assisted reproductive technology market is supported by significant demand for fertility care, with Health Canada reporting that one in six Canadian adults is affected by infertility. Provincial and territorial programs provide varying levels of coverage for in-vitro fertilization and other fertility treatments, while the federal government expanded the Medical Expense Tax Credit in 2022 to include additional fertility-related expenses, supporting access to assisted reproductive services.
The Middle East and Africa assisted reproductive technology market is expected to grow at a CAGR of 7.21%, supported by improving fertility care infrastructure, increasing access to assisted reproductive procedures, and growing awareness of fertility treatment options. The UAE assisted reproductive technology market is expected to benefit from Abu Dhabi’s continued investment in fertility care and reproductive-health innovation, with the Department of Health – Abu Dhabi reporting 14 specialized assisted reproductive technology centers and a 59% IVF success rate in 2026, while its new reproductive-health program aims to raise IVF success rates to 80% by 2030 through advanced healthcare, genomic, research, and clinical capabilities.
The Africa assisted reproductive technology market is expected to benefit from growing efforts to strengthen infertility care, with WHO’s 2025 global infertility guideline providing 40 recommendations for prevention, diagnosis, and treatment and calling for fertility care to be integrated into national health strategies and financing. WHO is also conducting a 2026–2036 foresight process to identify future priorities for sexual and reproductive health and rights, including emerging fertility-care needs.
The assisted reproductive technology market is highly fragmented, with fertility clinics, reproductive healthcare providers, pharmaceutical companies, medical device manufacturers, laboratory technology providers, fertility service networks, and specialized reproductive medicine companies competing across in vitro fertilization, fertility preservation, embryo testing, donor services, and related treatments. Established players compete primarily on clinical success rates, treatment quality, technological capabilities, laboratory infrastructure, physician expertise, patient care, regulatory compliance, treatment portfolio, geographic reach, and brand reputation, with leading players such as CooperSurgical, Vitrolife, Ferring Pharmaceuticals, Monash IVF Group, and IVI RMA Global estimated to account for approximately 40% of the global market based on their clinical and laboratory capabilities, product portfolios, geographic presence, service networks, and competitive positioning.
Emerging and regional players within the assisted reproductive technology market ecosystem compete through affordable treatment options, specialized fertility services, personalized care, advanced laboratory technologies, flexible treatment packages, digital patient engagement, localized services, and innovative reproductive solutions to address specific patient needs and strengthen their market presence. These players also focus on improving patient experience, expanding specialized treatment offerings, and adopting advanced laboratory technologies to differentiate their services and broaden their market reach.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Organ Preservation Market Size, Share, Growth, Analysis, Report, 2034
Bacteriophage Market Size, Share, Growth, Analysis, 2034
Epigenetics Market Size, Share, Growth, Analysis, Report, 2034
Biobanking Market Size, Share, Growth, 2034
Cell Therapy Manufacturing Market Size, Share, Growth, 2034
Clinical Oncology Next Generation Sequencing Market Size, 2034
We are featured on:
sales@straitsresearch.com